Asia Pacific Anti diabetic Biosimilars Market By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)and Geography  

Purchase Option

$ 3000
$ 4400
$ 4600
$ 6900

Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

Asia Pacific Anti diabetic Biosimilars Market report gives a comprehensive outlook across the regions with special emphasis on key countries such as Australia, China, India, Japan, Indonesia, Vietnam, South Korea, and Rest of APAC. The report gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, disease type, distribution channel and countries. This report studies Asia Pacific Antidiabetic Biosimilars Market dynamics elaborately to identify the current market trends and drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes competition analysis with a vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the countries and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers..

Asia Pacific Anti Diabetic Biosimilars Market Summary

Study Period

2023-29

Base Year

2022

CAGR

x%

Largest Market

N/A

Fastest Growing Market

N/A
Asia Pacific Anti diabetic Biosimilars Market Dynamics

Increase in the prevalence of diabetes majorly in China and India, Patent expiries of block buster drugs and promising product pipeline and Rise in R&D activities for the innovation of Insulin biosimilars

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Asia Pacific Anti Diabetic Biosimilars Market Segmentation

Drug Class
  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • ?-glucosidase Inhibitos
  • GLP-1 Agonists
  • Others
Disease Type
  • Type-I Diabetes
  • Type-II Diabetes
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Country
  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Executive Summary
  2. Asia Pacific Anti diabetic Biosimilars Market Introduction
    • Asia Pacific Anti diabetic Biosimilars Market – Taxonomy
    • Asia Pacific Anti diabetic Biosimilars Market –Definitions
      • Drug Class
      • Disease Type
      • Distribution Channel
  1. Asia Pacific Anti diabetic Biosimilars Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Asia Pacific Anti diabetic Biosimilars Market Dynamic Factors - Impact Analysis
    • Asia Pacific Anti diabetic Biosimilars Market – Competition Landscape
    • Epidemiology
  2. Asia Pacific Anti diabetic Biosimilars Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Asia Pacific Anti diabetic Biosimilars Market, By Drug Class, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Insulin
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Biguanides
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Sulfonyl Ureas
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Thiazolidinediones
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Di Peptidyl Peptidase (DPP)-IV Inhibitors
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • ?-glucosidase Inhibitos
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • GLP-1 Agonists
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Asia Pacific Anti diabetic Biosimilars Market Forecast, By Disease Type,2013 - 2017 and Forecast, 2018 – 2024
    • Type-I Diabetes
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Type-II Diabetes
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Asia Pacific Anti diabetic Biosimilars Market Forecast, By Distribution Channel, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Asia Pacific Anti diabetic Biosimilars Market Forecast, By Country, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Japan
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • China
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • India
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Australia & New Zealand
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • ASEAN
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • South Korea
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Rest of Asia Pacific
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia Pacific Anti diabetic Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel and Country, 2018 – 2024
  2. Japan Anti diabetic Biosimilars MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Insulin
      • Biguanides
      • Sulfonyl Ureas
      • Thiazolidinediones
      • Di Peptidyl Peptidase (DPP)-IV Inhibitors
      • ?-glucosidase Inhibitos
      • GLP-1 Agonists
      • Others
    • Disease Type Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Type-I Diabetes
      • Type-II Diabetes
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Japan Anti diabetic Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, 2018 – 2024
    • Japan Anti diabetic Biosimilars Market Dynamics – Trends
  3. China Anti diabetic Biosimilars Market Analysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Insulin
      • Biguanides
      • Sulfonyl Ureas
      • Thiazolidinediones
      • Di Peptidyl Peptidase (DPP)-IV Inhibitors
      • ?-glucosidase Inhibitos
      • GLP-1 Agonists
      • Others
    • Disease Type Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Type-I Diabetes
      • Type-II Diabetes
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • China Anti diabetic Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, 2018 – 2024
    • China Anti diabetic Biosimilars Market Dynamics – Trends
  4. India Anti diabetic Biosimilars MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Insulin
      • Biguanides
      • Sulfonyl Ureas
      • Thiazolidinediones
      • Di Peptidyl Peptidase (DPP)-IV Inhibitors
      • ?-glucosidase Inhibitos
      • GLP-1 Agonists
      • Others
    • Disease Type Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Type-I Diabetes
      • Type-II Diabetes
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • India Anti diabetic Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, 2018 – 2024
    • India Anti diabetic Biosimilars Market Dynamics – Trends
  5. Australia & New Zealand Anti diabetic Biosimilars Market Analysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Insulin
      • Biguanides
      • Sulfonyl Ureas
      • Thiazolidinediones
      • Di Peptidyl Peptidase (DPP)-IV Inhibitors
      • ?-glucosidase Inhibitos
      • GLP-1 Agonists
      • Others
    • Disease Type Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Type-I Diabetes
      • Type-II Diabetes
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Australia & New Zealand Anti diabetic Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, 2018 – 2024
    • Australia & New Zealand Anti diabetic Biosimilars Market Dynamics – Trends
  6. ASEAN Anti diabetic Biosimilars MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Insulin
      • Biguanides
      • Sulfonyl Ureas
      • Thiazolidinediones
      • Di Peptidyl Peptidase (DPP)-IV Inhibitors
      • ?-glucosidase Inhibitos
      • GLP-1 Agonists
      • Others
    • Disease Type Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Type-I Diabetes
      • Type-II Diabetes
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • ASEAN Anti diabetic Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, 2018 – 2024
    • ASEAN Anti diabetic Biosimilars Market Dynamics – Trends
  7. South Korea Anti diabetic Biosimilars MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Insulin
      • Biguanides
      • Sulfonyl Ureas
      • Thiazolidinediones
      • Di Peptidyl Peptidase (DPP)-IV Inhibitors
      • ?-glucosidase Inhibitos
      • GLP-1 Agonists
      • Others
    • Disease Type Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Type-I Diabetes
      • Type-II Diabetes
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • South Korea Anti diabetic Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, 2018 – 2024
    • South Korea Anti diabetic Biosimilars Market Dynamics – Trends
  8. Rest of Asia Pacific Anti diabetic Biosimilars MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Insulin
      • Biguanides
      • Sulfonyl Ureas
      • Thiazolidinediones
      • Di Peptidyl Peptidase (DPP)-IV Inhibitors
      • ?-glucosidase Inhibitos
      • GLP-1 Agonists
      • Others
    • Disease Type Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Type-I Diabetes
      • Type-II Diabetes
    • Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Rest of Asia Pacific Anti diabetic Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, 2018 – 2024
    • Rest of Asia Pacific Anti diabetic Biosimilars Market Dynamics – Trends
  9. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Biocon (India)
      • Merck Sharp & Dohme Corporation (U.S.)
      • Boehringer Ingelheim GmbH (Germany)
      • Eli Lilly & Co. (U.S.)
      • Sanofi-aventis U.S. LLC (U.S.)
      • Samsung Bioepis (Samsung BioLogics) (South Korea)
      • Mylan N.V. (U.S.)
      • Wockhardt (India)
  1. Research Methodology
  2. Key Assumptions and Acronyms
  • Biocon (India)
  • Merck Sharp & Dohme Corporation (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly & Co. (U.S.)
  • Sanofi-aventis U.S. LLC (U.S.)
  • Samsung Bioepis (Samsung BioLogics) (South Korea)
  • Mylan N.V. (U.S.)
  • Wockhardt (India)